Pioneering therapies for people with neurological disorders
Unique approach to promote
synaptogenesis and enhance synaptic function
Through molecular screening, we identified a novel compound that can selectively elevate intracellular magnesium at the synaptic terminal. In vivo, this compound increases synaptic density, function, and plasticity, and improves learning and memory.
ADHD - Phase 2b/3 trial
Depression - Phase 2b/3 trial
Alzheimer's Disease - Phase 2b/3 trial
Nutraceutical for improving brain health in healthy people
Proprietary compound shown to improve brain health. Marketed since 2012 with approximately 500,000 customers / year.